Bashar and Begam: Chloroquine and Hydroxychloroquine: Are they really wonder drugs for COVID 19?


Introduction

Since the first case was reported in December 2019 from Wuhan, China, infection with the severe acute respiratory coronavirus 2 (SARS-CoV-2) i.e. COVID 19, has become a worldwide pandemic.1, 2 The pandemic has also challenged the slow and highly regulated drug-approval process across the globe.3 On March 28, 2020, the U.S. Food & Drug Authority(FDA), the highest drug approving agency across the world, authorized use of the antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) to treat COVID-19 patients without any clinical trial data and despite inconclusive clinical evidence of effectiveness.4 Before that, on 22 March, 2020, National task force for COVID-19 constituted by Indian Council for Medical research (ICMR) recommended the use of hydroxyl-chloroquine for prophylaxis of SARS-Cov-2 infection in high risk individuals.5 The recommendation was approved by Drug controller general of India(DCGI) for restricted use in emergency situations.

Interest in these drugs was sparked by the conviction that most COVID-19 patients are probably in an antiviral-susceptible stage before clinical presentation. Following a primary phase marked by the usual respiratory symptoms, fevers, and malaise, patients most affected by COVID-19 develop a severe inflammatory respiratory illness, driven largely by the host immune response. Laboratory data show evidence of massive inflammation, including elevated C-reactive protein, ferritin, and interleukin-6. CQ and HCQ have demonstrated activity in vitro against SARS-CoV, SARS-CoV-2, and other viruses.6, 7, 8 The mechanism is not clearly understood but it involves raising the pH of cellular endosomes, rendering less efficient the process of viral entry, replication, and infection and interference with glycosylation of cellular receptors for the virus. In addition, these drugs also appear to reduce host cell autophagy.9 Given these apparent antiviral and immunomodulatory effects, CQ/HCQ seemed promising.10

Emergency use Authorization of CQ/HCQ by the FDA for COVID-19 occurred primarily after the extensive publicity cause due to a small non-randomized study, of 36 patients with confirmed COVID-19; 22 having upper respiratory tract infections, 8 having lower respiratory tract infections, and 6 having no symptoms.11 Of these patients, 20 received HCQ (600 mg daily) and 16 did not (control patients). Among the HCQ patients, 6 also received azithromycin (AZM; 500 mg on day 1, 250 mg on days 2–5) as a bacterial superinfection prophylaxis. Within 6 days, virologic clearance was seen in 70% of HCQ recipients and in 12.5% of controls. All patients treated with HCQ+AZM cleared virus compared with 57.1% who received HCQ alone only.11 These findings were not convincing and the effect was purely microbiological and not clinical. Further, the study was not optimally designed and was potentially subject to bias.

Notably, in previous epidemics of chikungunya, dengue, and influenza, the apparent in vitro antiviral effects of CQ/HCQ did not translate into clinical benefits.12 The first randomized study of HCQ in COVID-19 patients from China had only 30 patients from a single centre and did not show any clinical benefit.13 A second report published February 15, 2020, indicated that there were better outcomes associated with CQ therapy than in controls in a review of 100 patients, but the full results have yet to be published in a peer-reviewed journal.14

Beyond the substantial doubts about their efficacy, CQ and HCQ are not without toxicity. Photosensitivity, gastrointestinal side effects, and other toxicities — while rare — may be augmented in severely ill COVID-19 patients. Of particular concern is QT prolongation due to these agents, as myocarditis and cardiomyopathy appear to be relatively common complications in patients with severe COVID-19.15, 16 Highlighting these concerns, in a double-blind, randomized trial in Brazil of two doses of CQ (600 mg twice daily for 10 days or 450 mg twice daily for 5 days) for hospitalized patients with COVID-19 recently, the higher-dose arm was discontinued per data safety monitoring board for increased mortality.17 An additional retrospective review of 368 male patients hospitalized with COVID-19 in U.S. veterans medical centers, released as non–peer-reviewed preprint on April 21, 2020, raised a similar concern.18 Although HCQ recipients and non-recipients differed in several baseline characteristics that could have influenced the findings, the risk for death was higher in the HCQ group than in the non-HCQ group (adjusted hazard ratio with HCQ vs. without, 2.6).18

Conclusion

Although new treatment approaches to the management of COVID-19 are required rapidly and desperately keeping in view the pandemic situation, most of the available information in relation to the use of CQ/HCQ for COVID-19 comes from studies that were either poorly designed or available in only non–peer-reviewed preprints. Placebo-controlled studies evaluating the role of CQ/HCQ as postexposure prophylaxis, in outpatient clinics (mild disease), and in hospitalized patients have now been started. Given the currently available limited efficacy data and the grave concerns regarding safety, we believe that CQ/HCQ should not be used for COVID-19 until controlled clinical trials clearly demonstrate the benefits outweighing potential harms.

Source of Funding

None.

Conflict of Interest

None.

References

1 

D Cucinotta M Vanelli WHO declares COVID-19 a pandemicActa Biomed20209115760

2 

A. Spinelli G. Pellino COVID-19 pandemic: perspectives on an unfolding crisisBr J Surg2020107778570007-1323Wiley

3 

Benjamin N. Rome Jerry Avorn Drug Evaluation during the Covid-19 PandemicN Engl J Med202038224228240028-4793, 1533-4406Massachusetts Medical Society

4 

Food and Drug Administration2020https://www.fda.gov/media/136534/download

5 

Advisory on the use of Hydroxychloroquine for SARS- COV-2 Infection. Ministry of health & family welfarehttps://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf

6 

M Wang R Cao L Zhang Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res20203026971

7 

Christophe Biot Wassim Daher Natascha Chavain Thierry Fandeur Jamal Khalife Daniel Dive Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral ActivitiesJ Med Chem2006499284590022-2623, 1520-4804American Chemical Society (ACS)

8 

J Liu R Cao M Xu Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discov202061616

9 

Y Yan Z Zou Y Sun Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal modelCell Res20132323002

10 

Philippe Colson Jean-Marc Rolain Didier Raoult Chloroquine for the 2019 novel coronavirus SARS-CoV-2Int J Antimicrob Agents20205531059230924-8579Elsevier BV

11 

P Gautret J C Lagier P Parola Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInt J Antimicrob Agents2020105949

12 

N I Paton L Lee Y Xu Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trialLancet Infect Dis20111167783

13 

J Chen D Liu L Liu A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)J Zhejiang Univ (Med Sci)2020491

14 

J Gao Z Tian X Yang Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141723

15 

James M. Sanders Marguerite L. Monogue Tomasz Z. Jodlowski James B. Cutrell Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA20200098-748410.1001/jama.2020.6019American Medical Association (AMA)

16 

E Chorin M Dai E Shulman The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycinNat Med2020

17 

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)medRxiv202010.1101/2020.04.07.20056424

18 

J Magagnoli S Narendran F Pereira Tammy H. Cummings James W. Hardin S. Scott Sutton Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19Med (N Y)202010.1016/j.medj.2020.06.001



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


  • Article highlights
  • Article tables
  • Article images

View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.jchm.2020.013


Article Metrics






Article Access statistics

Viewed: 834

PDF Downloaded: 452



Wiki in hindi